GRAIL (NASDAQ:GRAL) CFO Aaron Freidin Sells 655 Shares

GRAIL, Inc. (NASDAQ:GRAL) CFO Aaron Freidin sold 655 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $53.01, for a total transaction of $34,721.55. Following the sale, the chief financial officer directly owned 308,967 shares in the company, valued at $16,378,340.67. This trade represents a 0.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Aaron Freidin also recently made the following trade(s):

• On Monday, March 9th, Aaron Freidin sold 2,492 shares of GRAIL stock. The stock was sold at an average price of $47.89, for a total value of $119,341.88.
• On Monday, March 2nd, Aaron Freidin sold 9,573 shares of GRAIL stock. The shares were sold at an average price of $50.17, for a total value of $480,277.41.

GRAIL Stock Down 0.8%

Shares of NASDAQ:GRAL traded down $0.41 during trading on Monday, hitting $49.82. The stock had a trading volume of 1,587,964 shares, compared to its average volume of 2,112,505. GRAIL, Inc. has a 12-month low of $20.44 and a 12-month high of $118.84. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of -4.46 and a beta of 5.21. The stock has a 50-day simple moving average of $88.14 and a two-hundred day simple moving average of $77.99.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($2.44) earnings per share for the quarter, topping the consensus estimate of ($3.33) by $0.89. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.58%. The company had revenue of $43.60 million for the quarter, compared to the consensus estimate of $43.33 million. As a group, sell-side analysts forecast that GRAIL, Inc. will post -15.15 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Guggenheim upped their price target on shares of GRAIL from $100.00 to $130.00 and gave the company a “buy” rating in a report on Monday, January 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. Robert W. Baird set a $82.00 target price on GRAIL in a research note on Friday, February 20th. Canaccord Genuity Group dropped their target price on GRAIL from $105.00 to $80.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Finally, TD Cowen began coverage on GRAIL in a report on Thursday, February 19th. They issued a “hold” rating and a $114.00 price target for the company. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $90.17.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Perigon Wealth Management LLC raised its position in shares of GRAIL by 0.7% in the fourth quarter. Perigon Wealth Management LLC now owns 19,450 shares of the company’s stock worth $1,665,000 after acquiring an additional 133 shares during the period. Parallel Advisors LLC boosted its stake in shares of GRAIL by 5.2% during the 4th quarter. Parallel Advisors LLC now owns 2,667 shares of the company’s stock worth $228,000 after acquiring an additional 133 shares in the last quarter. Westmount Partners LLC grew its position in shares of GRAIL by 1.8% during the 4th quarter. Westmount Partners LLC now owns 8,279 shares of the company’s stock valued at $709,000 after acquiring an additional 150 shares during the period. Comerica Bank increased its stake in shares of GRAIL by 59.2% in the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after purchasing an additional 173 shares in the last quarter. Finally, Whittier Trust Co. increased its stake in shares of GRAIL by 19.3% in the 4th quarter. Whittier Trust Co. now owns 1,114 shares of the company’s stock valued at $95,000 after purchasing an additional 180 shares in the last quarter.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.